Glenmark Pharmaceuticals receives ANDA approval for fulvestrant injection
MUMBAI, India — Glenmark has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for fulvestrant injection, 250 mg/5 mL (50 mg/mL), a generic version of Faslodex Injection, 250 mg/5 mL (50 mg/mL), of AstraZeneca Pharmaceuticals LP. According to IQVIATM sales data for the 12 month period ending June 2019,
